Rohit Mehra

This study identifies a stress-lipid kinase axis in NEPC driven by PIKfyve, revealing a synthetic vulnerability between PIKfyve and FASN that can be exploited for therapeutic targeting.

This study identifies NNMT as a tumor suppressor in prostate cancer that regulates SAM availability, mTORC1 signaling, and chromatin methylation, revealing a therapeutic strategy using dietary methionine restriction and mTORC1 inhibition.

The paper identifies a transcriptional transition state in ccRCC cells that drives sarcomatoid transformation and enhances immunotherapy response via macrophage and T-cell interactions.

This study identifies PIKfyve as a targetable vulnerability in pancreatic cancer by showing its role in lipid metabolism and synthetic lethality with KRAS-MAPK inhibitors.

This study identifies a therapeutic vulnerability in POU2F-POU2AF-driven cancers by showing that targeting the mSWI/SNF complex with a PROTAC degrader reduces tumor growth in preclinical models.